Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation email@example.com
SPECIAL REPORT #20.12
Coronavirus Treatment Tracking
Kevzara from Sanofi and Regeneron and Actemra from Roche are both selective interleukin- 6 (IL-6) inhibitors, approved for the treatment of rheumatoid arthritis, which have recently been tentatively repurposed to treat COVID-19.
Yesterday the fate of these two products took different paths.
Sanofi and Regeneron indicated that they would slow down on their current ongoing phase 3 study with Kevzara (sarilumab) after early results did not meet the expectations in severely ill coronavirus patients. The previous study has now been amended with a higher dose (400 mg of Kevzara) to include only patients requiring mechanical ventilation, a subset where a small positive outcome had been identified.
At the same time, a report from a program at the Assitance Publique-Hôpitaux de Paris (AP-HP) suggests that Actemra (tocilizumab) from Roche did “significantly” better in reducing the number of deaths or needs for ventilators at day 14, although the full data have not been disclosed. The ongoing CORIMUNO-19 program which encompasses several other trials on COVID-19 had enrolled 129 patients with moderate to severe cases in a randomized trial. Roche indicated that the results gathered from 65 patients treated for up to 14 days with Actemra versus 64 patients receiving standard of care, are “early data”. AP-HP internal sources told us that the results of the study are being analysed by a peer review body and will be sent for publication in the days to come.
The most frenzy media attention is now focused on Roche’s own phase 3 COVACTA study with Actemra, which started three weeks ago, and where a full dataset will soon become available.
Hope you are all doing fine
Paris, April 28, 2020
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.